A Randomized Controlled Trial of a Novel Mixed Monoamine Reuptake Inhibitor in Adults with ADHD

DSpace/Manakin Repository

A Randomized Controlled Trial of a Novel Mixed Monoamine Reuptake Inhibitor in Adults with ADHD

Citable link to this page

. . . . . .

Title: A Randomized Controlled Trial of a Novel Mixed Monoamine Reuptake Inhibitor in Adults with ADHD
Author: Klint, Thorsten; Adler, Lenard; West, Scott; Wesnes, Keith; Graff, Ole; Mikkelsen, Birgit; Wilens, Timothy Edwin

Note: Order does not necessarily reflect citation order of authors.

Citation: Wilens, Timothy E., Thorsten Klint, Lenard Adler, Scott West, Keith Wesnes, Ole Graff, and Birgit Mikkelsen. 2008. A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD. Behavioral and Brain Functions : BBF 4: 24.
Full Text & Related Files:
Abstract: Background: NS2359 is a potent reuptake blocker of noradrenalin, dopamine, and serotonin. The aim of the study was to investigate the efficacy, safety and cognitive function of NS2359 in adults with a DSM IV diagnosis of ADHD. Methods: The study was a multi-centre, double-blind, randomized placebo-controlled, parallel group design in outpatient adults (18–55 years) testing 0.5 mg NS2359 vs. placebo for 8 weeks. Multiple assessments including computerized neuropsychological evaluation were performed. Results: There was no significant difference between NS2359 (n = 63) versus placebo (n = 63) on the primary outcome measure reduction in investigator rated ADHD-RS total score (7.8 versus 6.4; p less than 0.45). However, in subjects with the inattentive subtype, there were significantly more responders in the NS2359 group compared to placebo (41% versus 7%; p less than 0.01). For all secondary variables (ADHD-RS patient rated; The Conners Adult ADHD Scale; The Brown Adult Scale, and CGI-improvement scale) there were no significant differences between the two groups; however, in the inattentive subgroup, the response to treatment was significantly larger than to placebo. NS2359 improved composite factor scores of attention, episodic- and working memory. No serious adverse events were reported with insomnia, headaches and loss of appetite most commonly reported as side effects. Conclusion: No overall effect of NS2359 was found on overall symptoms of ADHD. There was also a modest signal of improvement in the inattentive adults with ADHD and cognition warranting further exploration using differing doses.
Published Version: doi:10.1186/1744-9081-4-24
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442604/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:4817628

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters